<DOC>
	<DOCNO>NCT03037645</DOCNO>
	<brief_summary>Phase 1b ( Dose Escalation ) primarily CLL/SLL patient evaluate safety pharmacology self-administered twice day oral dos begin 25 mg/dose 4 week succeed cohort escalate dos establish dose limit toxicity , recommend Phase 2 dose . Patient data assess authorize dose escalation cohort . Phase 2 ( Cohort Expansion ) follow cohort use recommend dose explore clinical activity , safety , pharmacology SNS-062 monotherapy .</brief_summary>
	<brief_title>Safety , PK , PD , Antitumor Activity SNS-062 B Lymphoid Cancers</brief_title>
	<detailed_description>Phase 1b ( Dose Escalation ) This portion study evaluate safety pharmacology range SNS-062 dose level administer subject previously treat B-lymphoid malignancy , include : chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , lymphoplasmacytoid lymphoma/Waldenström 's macroglobulinemia ( LPL/WM ) , mantle cell lymphoma ( MCL ) . All subject self-administer SNS-062 orally BID . The dose-limiting toxicity ( DLT ) window 4 week ( 1 cycle length ) . Assessments DLT window perform 4-week cycle . Cohorts 3 6 subject sequentially enrol progressively high dose level SNS-062 use standard 3+3 dose-escalation design . Based pattern dose-limiting toxicity ( DLTs ) observe first cycle ( 4 week ) , escalation proceed define maximum tolerate dose ( MTD ) and/or recommend dose ( RD ) may MTD low dose . An additional 6 subject may accrue MTD RD confirm SNS-062 safety pharmacology prelude clinical evaluation . Assessments regard DLTs dose escalation perform SRC comprising , limited , principal investigator , medical monitor study sponsor drug safety representative . Phase 2 ( Cohort Expansion ) This portion study provide cohort expansion explore clinical activity , safety , pharmacology SNS-062 monotherapy . Accrual enrollment disease mutation specific cohort . Subjects self-administer SNS-062 orally RD SNS-062 identify Phase 1b portion study . Study personnel meet regularly ass efficacy safety cohort .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Inclusion Criteria ( Key factor list ) : Eastern Cooperative Oncology Group Performance Status 0 1 . Confirmed malignancy relapsed/refractory disease ≥ 2 line standard systemic therapy include prior BTK inhibitor therapy CLL , LPL/WM MCL . Presence measurable disease various assessment depend specific cancer type . Current medical need therapy Blymphoid malignancy due diseaserelated symptom . Exclusion Criteria ( Key factor list ) : Known central nervous system malignancy . History malignancy except adequately treat ( e.g. , local cancer skin , cervix breast cancer , noninvasive bladder cancer , prostate cancer stag 1 2 complete remission ) . Significant cardiovascular disease electrocardiogram ( ECG ) abnormalities Ongoing risk bleed due bleed diathesis , platelet function disorder , uncontrolled peptic ulcer disease , oral anticoagulation warfarin . Evidence ongoing systemic bacterial , fungal viral infection start drug therapy . Demonstrated intolerance BTK inhibitor show discontinuation due adverse effect . Use moderate strong inhibitor inducer CYP3A4 within 7 day prior start study therapy ( e.g. , antibiotic , antifungal , anticonvulsant , grapefruit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>Hematological disease</keyword>
	<keyword>Relapsed</keyword>
	<keyword>cancer</keyword>
	<keyword>malignancy</keyword>
	<keyword>SNS-062</keyword>
	<keyword>B-lymphoid</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Small lymphocytic lymphoma</keyword>
	<keyword>Lymphoplasmacytoid lymphoma</keyword>
	<keyword>Waldenström 's macrogloulinemia</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>LPL</keyword>
	<keyword>WM</keyword>
	<keyword>MCL</keyword>
	<keyword>Refractory</keyword>
</DOC>